VSTMVerastem, Inc.

$388M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$21M

Net Income

-$22M

EPS (Diluted)

$-1.41

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$100M

Total Liabilities

$47M

Stockholders' Equity

$54M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$500,000	-100.0%
Gross Profit	$0	$500,000	-100.0%
Operating Income	-$21M	-$16M	-34.2%
Net Income	-$22M	-$17M	-29.9%

Revenue Segments

Sale of COPIKTRA license and related assets

$3M100%

VSTM Q2 2022 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena